Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer
TIER-PC is an adaptive model of delivering palliative care that provides the right level of
care to the right patients at the right time. It represents an adaption of the Mount Sinai
PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care. ...
Age: 18 years - 66+
Gender: All
First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device
The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial
with the goal of determining the safety of TheraSphere PCa device in patients with clinically
localized prostate cancer across US-based centers.
Age: 50 years - 66+
Gender: Male
Evaluating the Efficacy of the eNav Toolkit to Improve Colorectal Cancer Screening
The purpose of this research study is to evaluate the efficacy of a digital navigation tool,
called the eNav to improve colorectal cancer screening uptake among patients treated at
federally qualified health centers (FQHC)s. The digital navigation tool includes a we...
Age: 45 - 75 years
Gender: All
Mobile Ostomates Resources for Patients and Caregivers
The scope of this research is to examine the acceptability and feasibility of a refined web-based intervention ("STOMA Care" app) by conducting a randomized pilot consisting of bladder and colorectal cancer patients scheduled for ostomy surgery at Mount Sinai Health Sys...
Age: 21 years - 66+
Gender: All
PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System
The goal of this clinical trial is to evaluate the safety of the AQUABEAM Robotic System in
treating patients with localized prostate cancer. Participants will go through baseline and
follow up assessments up to 12 months.
Age: 40 years - 66+
Gender: Male
A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity
(DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion
(RDE) of INCA033989 administered in participants with myeloproliferative neoplasm...
Age: 18 years - 66+
Gender: All
A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer
The purpose of this clinical study is to assess the safety and efficacy of hSTC810 and
paclitaxel combination therapy in patients with relapsed or refractory extensive stage small
cell lung cancer.
Age: 18 years - 66+
Gender: All
A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
This trial is a phase 1b/2, open-label, multicenter study of GC012F, a CD19/BCMA dual
CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.
Age: 18 years - 66+
Gender: All
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunother...
Age: 18 years - 66+
Gender: All
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
This study is researching an investigational drug called fianlimab (also called REGN3767)
with two other medications called cemiplimab and chemotherapy, individually called a "study
drug" or collectively called "study drugs". 'Investigational' means that the study d...
Age: 18 years - 66+
Gender: All
The Ambient Light Multiple Myeloma Study
The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cell Transplantation. T...
Age: 21 years - 66+
Gender: All
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the
combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the
treatment of pre- and postmenopausal women and men who have previously received ribo...
Age: 18 years - 66+
Gender: All
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramuciruma...
Age: 18 years - 66+
Gender: All
A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
The main purpose of this study is to learn more about the safety, side effects, and
effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that line the
urinary system and other solid tumor cancers that have a change in a particular gene (known...
Age: 18 years - 66+
Gender: All
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course
chemoradiation in patients with stage II-III rectal cancer. Combination chemotherapy drugs,
such as FOLFIRINOX (fluorouracil, irinotecan, leucovorin, and oxaliplatin), FOLFOX
...
Age: 18 years - 66+
Gender: All
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical
trials to study cancer treatment directed by genetic testing. Patients with solid tumors that
have spread to nearby tissue or lymph nodes (locally advanced) or have spread to oth...
Age: Birth - 66+
Gender: All
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial
This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy
(paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be
removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally
advance...
Age: 18 years - 66+
Gender: All
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as
monotherapy or in combination with ultralow dose gemcitabine in participants with
platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma
ba...
Age: 18 years - 66+
Gender: All
Intravesical BCG vs GEMDOCE in NMIBC
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG. The ...
Age: 18 years - 66+
Gender: All
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in
participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV)
infusion.
Age: 18 years - 66+
Gender: All